Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

Background. Anlotinib is an effective targeted therapy for advanced non-small-cell lung cancer (NSCLC) and has been found to mediate chemoresistance in many cancers. However, the underlying molecular mechanism of anlotinib mediates cisplatin (DDP) resistance in NSCLC remains unclear. Methods. Cell v...

Full description

Saved in:
Bibliographic Details
Main Authors: Lile Wang, Lu Xu, Shuhua Han, Xiaoli Zhu
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Canadian Respiratory Journal
Online Access:http://dx.doi.org/10.1155/2024/2632014
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items